Patient group
Erwachsene mit neovaskulärer (feuchter) altersabhängiger Makuladegeneration
completed2020-03-15D series
Brolucizumab
Neovaskuläre altersabhängige Makuladegeneration
Open official case page ↗
- Brand
- Beovu®
- Manufacturer
- Novartis Pharma GmbH
G-BA action
final resolution
2020-09-03
Arzneimittel-Richtlinie/Anlage XII: Brolucizumab (Neovaskuläre altersabhängige Makuladegeneration)
Evidence-checked summary
The G-BA found no proven added benefit for Erwachsene mit neovaskulärer (feuchter) altersabhängiger Makuladegeneration. The appropriate comparator was - Ranibizumab oder Aflibercept. The G-BA issued a final resolution on 2020-09-03. The official page states that it took effect as follows: aufgehoben. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
G-BA result by patient group
Official case record
What happened, in source order
No inferred stages
Consultation record
Oral hearing and Wortprotokoll
2020-07-27
36 parsed turns
Oral hearing: Brolucizumab (Neovaskuläre altersabhängige Makuladegeneration)
Official Wortprotokoll · 8 pages
IQWiG comparison
Assessment record versus G-BA action
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
A20-23
matched
Brolucizumab (neovascular age-related macular degeneration) - Benefit assessment according to §35a Social Code Book V
Official assessment PDF · 32 pages
G-BA decisions
Distinct actions and documents
2020-09-03
final resolution
Arzneimittel-Richtlinie/Anlage XII: Brolucizumab (Neovaskuläre altersabhängige Makuladegeneration)
The G-BA found no proven added benefit for Erwachsene mit neovaskulärer (feuchter) altersabhängiger Makuladegeneration. The appropriate comparator was - Ranibizumab oder Aflibercept. The G-BA issued a final resolution on 2020-09-03. The official page states that it took effect as follows: aufgehoben. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
Official sources
Case document package
official case pageOfficial G-BA case pageOpen ↗comparator informationInformationen zur zweckmäßigen VergleichstherapieOpen ↗hearing transcriptWortprotokollOpen ↗decision textBeschlusstextOpen ↗decision rationaleTragende Gründe zum BeschlussOpen ↗summary documentationZusammenfassende DokumentationOpen ↗iqwig assessmentNutzenbewertung IQWiG, ausgetauscht am 03.09.2020Open ↗